Long-term peripheral blood counts and factors influencing long-term trilineage haematological recovery of consecutive patients in a single institution treated with high-dose chemotherapy (HDC) and ABMT or PSCT for solid tumours were examined. Patients with a relapse-free survival of Ͼ1 year were included in the analysis (n = 131). Peripheral blood counts were examined 6 months and yearly following transplantation. Median follow-up was 4.1 years (range 1-10+ years). Three years after transplantation 91% of patients had normal white blood counts (WBC), 94% normal haemoglobin (Hb) and 75% normal platelets. Trilineage recovery was complete in 70% (n = 83) at 3 years and 85% (n = 50) at 5 years. Recovery of Hb occurred before WBC and platelet recovery. Approximately 25% of patients displayed an elevated MCV throughout the follow-up period. These long-term results were independent of age, high-dose regimen, number of reinfused stem cells and stem cell source. Double (n = 12) vs single (n = 119) transplantations showed significantly slower trilineage recovery and higher MCV. No secondary graft failure, myelodysplasia or leukaemia was encountered. In conclusion, complete trilineage recovery after HDC followed by ABMT or PSCT occurs slowly. PSCT and ABMT are capable of maintaining long-term haematopoiesis. Slower recovery is seen after double transplantations. The results suggest lasting implications for bone marrow function after autologous transplantation. Bone Marrow Transplantation (2001) 27, 959-966.
pheral blood has been increasingly applied for a variety of disorders. Autologous bone marrow transplantation (ABMT) or peripheral stem cell transplantation (PSCT) permits the delivery of a higher, marrow-ablative dose of chemotherapy. In addition to patients with haematological diseases an increasing number of patients with solid tumours have undergone HDC with ABMT or PSCT during the last decade. 1 HDC with ABMT or PSCT is not considered standard treatment for solid tumours, therefore benefits have to be studied in randomised studies and balanced against the risks of the treatment, both in the short and long term. 2 Solid tumours treated with HDC followed by ABMT or PSCT include breast cancer, 3, 4 ovarian carcinoma, [5] [6] [7] relapsed germ cell tumours [8] [9] [10] and childhood sarcomas. 11, 12 In the last decade, a shift from bone marrow to peripheral blood as the source of haematopoietic stem cells has occurred. It has been shown that PSCT compared to ABMT offers faster short-term recovery of peripheral blood counts resulting in lower morbidity, mostly due to fewer infections and haemorrhagic periods and a reduced usage of blood products. 13 Abnormalities in haematopoiesis have been shown following transplantation. [14] [15] [16] [17] Decreased bone marrow cellularity has been shown to persist up to 3 years following allogeneic transplantation. 18 The number of colony-forming units (CFU-GM, BFU-E, CFU-Meg and TL-CFU) was shown to be diminished following autologous transplantation persisting for as long as 4-5 years. [19] [20] [21] [22] Patients relapsing after transplantation showed decreased haematological tolerance to reinduction chemotherapy. 23 Radiotherapy after transplantation and infections during followup can lead to haematopoietic stress and temporary cytopenias have been described in such circumstances. 24 Clinical problems could therefore arise from the abnormalities in haematopoiesis following autologous transplantation.
Data about attaining and maintaining sustained long-term (ie Ͼ1 year) haematopoiesis following ABMT or PSCT are scarce. Some data are available from patients with haematological malignancies and/or after allogeneic transplantation with, in general, a follow-up of 1 year at the most. 18, 25, 26 Studies usually report that peripheral blood counts will normalise within 1 year after transplantation. 21, 23, 24, [27] [28] [29] [30] [31] [32] Factors influencing short-term recovery have been studied extensively. 20, 30, [33] [34] [35] [36] [37] Most studies found a correlation with stem cell source, number of infused stem cells and use of haematopoietic growth factors. Factors influencing longterm (Ͼ1 year) recovery in solid tumours after ABMT or PSCT have not been studied to date. The present study analyses whether patients attain normal peripheral blood counts after HDC followed by ABMT or PSCT and whether ABMT or PSCT is capable of maintaining sustained long-term haematopoiesis. Peripheral blood counts and factors influencing long-term trilineage recovery of all solid tumour patients (surviving relapse-free Ͼ1 year) in a single institution treated with HDC followed by ABMT or PSCT were studied.
Patients and methods

Patient characteristics
Data of all patients treated with HDC followed by ABMT, PSCT or both for solid tumours at the Department of Medical Oncology, University Hospital Groningen, The Netherlands, were analysed. Only patients surviving relapse-free for more than 1 year were included in this study. They were followed for this analysis until relapse, loss to follow-up, maximum follow-up of 10 years or end of study (1 January 2000) .
Marrow transplant conditioning regimen and supportive measures
High-dose regimens and abbreviations for different drugs are shown in Table 1 . Relapsed germ cell tumour was treated with CyVP16 (year 1987) or CTCy/CTCy (year 1995). Ovarian carcinoma was treated with CyVP16 (1982) (1983) (1984) (1985) , CyMi (year 1985) or MiM (1987 MiM ( -1988 . Locally advanced breast cancer (T 1-3 N 1-2 M 0 ) was treated with MiT (1990 MiT ( -1994 or CTCy (1993 CTCy ( -2000 , metastatic breast cancer (M 1 ) with MiM (1987 MiM ( -1993 or T/MMi (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) and T 4 breast cancer (T 4 N 0 M 0 ) with CyVP16 (1984 CyVP16 ( -1990 . Two patients originally supposed to receive T/MMi received only T and one patient supposed to receive CTCy/CTCy received only one course of CTCy. Three separate kinds of chemotherapy could be distinguished: cyclophosphamidebased regimens, mitoxantrone-based regimens and ablative regimens used for double transplantations. All patients were treated with selective gut decontamination. Granulocyte colony-stimulating growth factor (G-CSF) was administered subcutaneously since 1992 at a dose of 5 g/kg/day starting the day of stem cell reinfusion and was continued until the white blood count (WBC) was Ͼ3 × 10 9 /l on 2 consecutive days. Platelets were transfused if serum platelets fell below 20 × 10 9 /l or if bleeding occurred. Leukocyte-depleted blood was transfused when haemoglobin (Hb) was below 8 g/dl or if the patient had symptomatic anaemia. All blood products were irradiated.
Bone marrow harvest
Between 1982 and 1994, bone marrow was collected by multiple punctures from the posterior iliac crests under local anaesthesia with lidocaine. The marrow was aspirated in 10 ml disposable syringes and collected in Hanks' solution with hepes buffer and heparin. The marrow was centrifuged in a Haemonetics 30S apheresis machine (Haemonetics Corporation, Braintree, MA, USA). After sedimentation of red blood cells in a 10% hydroxy-ethyl starch solution and concentration of nucleated cells to 200 × 10 6 cells/ml, cryopreservation followed. A minimum of 2 × 10 8 nucleated cells/kg body weight were collected.
Mobilisation procedure and peripheral stem cell harvest
Peripheral stem cells were collected following a diseaseoriented course of chemotherapy and haematopoietic growth factors. Harvesting was performed via a dual lumen catheter using a Haemonetics MCS+ pheresis machine. CD34 + cells were stained using a monoclonal anti-CD34 (anti HPCA-2) and a quantitiation was performed by flow cytometry (FACSCalibur; Becton Dickinson, Woerden, The Netherlands). A target quantity of CD34 + cells of у5 × 10 6 /kg body weight was envisaged.
Marrow and stem cell cryopreservation
The bone marrow suspension or leukapheresis product was mixed with minimal essential medium (MEM) containing 20% dimethyl sulfoxide. The final cell suspension was transferred into freezing bags and frozen to −40°C with a computer-controlled cryopreservation device. The frozen cells were then transferred into the liquid phase of nitrogen and stored at −196°C.
Stem cell reinfusion
Immediately prior to infusion, the cryopreserved bone marrow or peripheral stem cells were rapidly thawed in a 40°C waterbath, aspirated in 50 ml syringes in a laminar flow cabinet and transfused through a double lumen Hickman catheter. Premedication consisted of steroids and antihistamines.
Radiotherapy
Radiotherapy was given to 115 of 122 (94%) of breast cancer patients post transplantation. Reasons for not administering radiotherapy included slow recovery of platelets in two patients. After mastectomy the target volume included the regional lymph nodes (46-50 Gy) and the chest wall (40-50 Gy). After breast-conserving therapy, the dose applied to the whole breast was 50 Gy with an extra dose to the area of the primary tumour of 16-20 Gy.
Haematological determinations
Hb, WBC, platelets and mean corpuscular volume (MCV) were determinated by standard techniques using an automated Coulter particle count (Coulter Electronics Nederland, Mijdrecht, The Netherlands). Long-term haematological recovery was defined as WBC of у4 × 10 9 /l, platelets of у150 × 10 9 /l and Hb of у12 g/dl. 21, 28, 30 Normal MCV was defined as 80-98 fl. 38 Following recovery from transplantation, patients were seen in our hospital on an outpatient basis at 3-month intervals. Peripheral blood counts and MCV were evaluated 6 months and 1 year after transplantation and yearly thereafter for a maximum of 10 years.
Statistical analysis
Most variables showed an asymmetric distribution, therefore, medians are presented. Long-term recovery was assessed using Kaplan-Meier probability curves and statistical comparison of curves was performed by the log-rank test. The prognostic value of different variables for longterm probability of reconstitution was assessed by multivariate analysis using the Cox multiple regression model. A P Ͻ 0.05 was considered statistically significant.
Results
Patient characteristics (Table 2)
From January 1982 to January 2000, 247 patients were treated with HDC followed by ABMT or PSCT for solid tumours. A total of 131 out of these 247 survived relapsefree for at least 1 year after ABMT or PSCT and were 
Long-term haematological recovery and time to normalisation of haematological parameters
Haemoglobin: One year after transplantation median Hb was 12.6 g/dl. Three years after transplantation a plateau was reached at 13.3-13.7 g/dl (Figure 1a) . The proportion of patients with a subnormal Hb (Ͻ12 g/dl) declined quickly in the first 3 years after transplantation (Figure 1b) . Five years after transplantation all patients had a normal Hb. Platelets: The number of platelets rose even more slowly after transplantation. Six months after transplantation median platelets was 130 × 10 9 /l, 1 year after transplantation 147 × 10 9 /l until it reached 257 × 10 9 /l at 10 years (Figure 3a) . One year after transplantation only 51% of the patients had normal platelet counts. Five years after transplantation 84% of patients had normal platelet counts (Figure 3b ).
Mean corpuscular volume
Median MCV just prior to HDC was 90.0 fl. Median MCV post transplantation was increased to 96 fl after 6 months and decreased to a steady-state level of about 92 fl after 5 years (Figure 4 ). Approximately one quarter of patients persisted with elevated MCV (Ͼ98 fl) during the complete follow-up period.
Bone Marrow Transplantation Figure 5 shows the cumulative proportion of patients reaching complete trilineage recovery in time after transplantation. One year after transplantation only 31% of patients had reached full trilineage recovery. Three and 5 years after transplantation these figures were 70% and 85%, respectively. No secondary graft failure was observed. No dependency of blood or platelet transfusion was seen beyond 6 months of follow-up. No myelodysplasia nor leukaemia were encountered.
Time to trilineage recovery
Analysis of factors influencing trilineage recovery and MCV
The trilineage recovery with a cyclophosphamide-based regimen as compared to a mitoxantrone-based regimen was not different (log-rank P = 0.38). The probability of reaching full trilineage recovery was lower for patients treated with two high-dose regimens (log-rank P = 0.0076) compared to patients treated with one regimen (Figure 6 ). No differences could be found in long-term trilineage recovery between patients receiving bone marrow, peripheral stem cells or both as source of haematopoietic stem cells. The number of patients with relapsed germ cell tumours and ovarian carcinoma was too small compared to the number of patients with breast cancer to detect differences between diagnoses. Using a Cox multiple regression model no significant relations could be found between age (P = 0.40) or number of reinfused stem cells (P = 0.19) and time to full trilineage recovery. The median dose of reinfused cells was 12 (range 3.3-28.8) × 10 6 CD34 + cells/kg body weight. All patients treated with one course of HDC and PSCT (n = 55) received more than 3.3 × 10 6 CD34 + cells/kg body weight. There was no relationship between use of haematopoietic growth factors and probability of reaching long-term full trilineage recovery or normalisation of WBC.
During the whole follow-up period median MCV was supranormal. In the first 4 years after transplantation median MCV was higher in patients treated with double vs single transplantation (MCV 101.7 vs 94.5 after 1 year (P Ͻ 0.001), MCV 99.4 vs 93.2 after 2 years (P = 0.002), MCV 100 vs 92.7 after 3 years (P = 0.004) and MCV 100.2 vs 93.2 after 4 years (P = 0.046)). Beyond 4 years the number of patients having received double transplantations was too small for comparison. MCV was significantly higher 1 year after transplantation in the group of patients treated with a mitoxantrone-based regimen vs a cyclophosphamidebased regimen (MCV 96.0 vs 93.5 (P = 0.012)). Beyond 1 year no significant differences were found, although MCV remained higher in the mitoxantrone treated patients. No differences in MCV were seen when age, number of reinfused stem cells or source of stem cells were considered.
Discussion
HDC followed by ABMT or PSCT has increasingly been applied in the last decade for patients with high-risk or relapsed solid tumours in whom conventional therapy offers limited chance of cure. The value of this treatment has been shown for some haematological diseases, but with the exception of promising results from a phase 2 study with relapsed germ cell tumours, 10 this has not yet been shown for solid tumours. Since short-term mortality and morbidity is decreasing, it is important to have insight in the long-term effects of ABMT and PSCT, including longterm haematological recovery.
In the present study of 131 patients from a single institution surviving relapse-free for more than 1 year after HDC followed by ABMT or PSCT, it was observed that for the whole group it takes several years for haematological parameters (WBC, Hb and platelets) to normalise completely. We used the same criteria for normal haematological parameters as most other studies that studied long-term haematological recovery.
21,28-30 After 5 years, 15% of patients in our study still had low values in one or more haematopoietic cell lineages. During the 10 years of followup however, blood counts rose steadily. Hb was the first parameter to normalise, followed by WBC and platelets. This slow long-term recovery is not in accordance with other data suggesting full trilineage recovery within 1 year. 21, 23, 24, [27] [28] [29] [30] [31] [32] Those data however are derived from haematological malignancies mostly, with a maximum follow-up of 1 year and therefore not necessarily fully comparable with our long-term data from solid tumours.
Our study population showed an increased median MCV throughout the follow-up period. Median MCV was normal just before HDC and was increased 6 months after transplantation to the end of the follow-up period. In patients with a high MCV we never found vitamin B12 or folate deficiency nor thyroid or liver dysfunction to explain the raised MCV. The high MCV suggests increased haematopoiesis by increased destruction of erythrocytes. It could be part of some form of myelodysplasia, a smouldering disease sometimes leading to leukaemia. Whether changes in the haematopoietic microenvironment, which have been observed after transplantation are responsible for this phenomenon is a subject for further research. 39 During the follow-up period, MCV was supranormal in roughly 25% of patients. The MCV was higher in patients receiving double transplantations and non-significantly higher in patients receiving single transplantations with a mitoxantrone-based regimen compared to a cyclophosphamide-based regimen. The elevated MCV is perhaps a sign of a more toxic regimen.
In a total follow-up of 558 patient-years, with 107 patients followed for more than 2 years, we did not encounter a single case of myelodysplasia (MD) or acute myeloid leukaemia (AML), the risk of which is reported to be increased following HDC with ABMT or PSCT. [40] [41] [42] [43] [44] [45] [46] It is suggested that prolonged dysfunction of the haematopoietic system leads to the emergence of these secondary diseases, 43, 47 typically occurring between 2 and 10 years after chemotherapy with the peak incidence after 5 years. Incidences up to 19.8% at 10 years have been reported following transplantation for non-Hodgkin's lymphoma. 41 The appearance of AML and MD seems to be more common after treatment of lymphomas with high-dose chemotherapy followed by ABMT or PSCT than of solid tumours and our results are in concordance with these data. 42, 44 The number of CD34
+ cells reinfused has been reported as a risk factor for AML and MD. 41 Several factors have been found to influence short-term haematopoietic recovery of patients undergoing ABMT or PSCT. Factors most often reported are prior exposure to fewer cycles of conventional-dose chemotherapy, 26, 33, 34, 37, 48 haematopoietic stem cell dose, 20, 21, [27] [28] [29] 33, [35] [36] [37] 49 total body irradiation as part of the high-dose regimen, 20 + cells did not result in faster recovery in these studies. Since 98% of our population received more than 5 × 10 6 CD34 + cells/kg, a correlation with long-term recovery was not to be expected.
Since the underlying diagnosis in 93% of our patient population was breast cancer, it was not possible to study differences in recovery according to underlying disease. It has been shown that underlying disease influences the short-time recovery of peripheral blood counts. Patients with acute myeloid leukaemia recover slower following HDC than patients with lymphoma and patients with solid tumours have a faster short-term recovery compared with haematological malignancies, possibly reflecting an underlying defect of the stem cell of the latter. 20, 30, 49, 52 Since 1992, haematopoietic growth factors have been available and since then PSCT has been increasingly used instead of ABMT, limiting ABMT to patients in whom it was impossible to collect peripheral stem cells. It has been shown that PSCT offers a quicker recovery with earlier short-term recovery of peripheral blood counts. 13 Our results showed no differences in long-term haematological recovery between patients receiving ABMT vs PSCT although follow-up with ABMT was longer. There has been some concern that PSCT might be inferior to ABMT in terms of long-term haematological recovery. 54, 55 Our data however suggest that peripheral stem cells are a safe and complete substitute for bone marrow in the long-term as source of stem cells. Our study also shows that secondary graft failure did not occur after ABMT or PSCT.
We found no significant differences between the single HDC regimens although the mitoxantrone-based regimen resulted in an initially increased MCV. In autologous bone marrow transplantation, regimens using total body irradiation, busulphan, melphalan or BCNU have been associated with slower short-term recovery. 20, 23, 34 We found significant differences in haematological recovery following one compared with two transplantations. This suggests (partial) recovery from original bone marrow after a single course of HDC, with a higher contribution from the transplant after double transplantation. Another explanation could be that damage to the marrow microenvironment (stroma) caused by the HDC results in slower haematological recovery. This stroma has an important role in the production of sufficient bone marrow cells. 19, 39, 48 Growth factors may also influence long-term recovery, as indicated by delayed recovery when GM-CSF is not administrated. 20 We found no differences in long-term recovery comparing patients treated with growth factors after transplantation and those who were not.
Prolonged dysfunction of the haematopoietic system can lead to poor tolerance to subsequent myelotoxic treatments. Few data are available concerning this subject. Brice et al 23 showed that chemotherapy for relapsing lymphoma after transplantation could be instituted without an increase in haematological toxicity. However, in this study it was more difficult to give additional chemotherapy after transplantation to the subgroup of patients with late platelet recovery after transplantation. The impairment of haematological recovery that we found might have clinical implications in planning chemotherapy or radiotherapy in case of relapse after transplantation.
In conclusion, we found that complete trilineage recovery after ABMT or PSCT for solid tumours occurs, but slowly. A significant proportion of patients has subnormal values in one or more cell lineages up to 10 years after transplantation. PSCT and ABMT are capable of maintaining long-term haematopoiesis after high-dose chemotherapy since no secondary failure was encountered. Slower recovery was seen with double transplantations. The results suggest lasting implications for bone marrow function after autologous transplantation.
